Catalyst Wire Dossier Catalyst Wire Dossier

STN1010904 ophthalmic suspension 0.03% and 0.1%

· Santen Inc.
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for STN1010904 ophthalmic suspension 0.03% and 0.1%, covering 2025-07-15 to 2025-07-15. Get the full timeline:

Most recent: Clinical Trial Update: A Multicenter Study Assessing the Efficacy and Safety of STN1010904 Ophthalmic Suspension 0.03% and 0.1% Compared With Vehicle in Subjects With Fuchs Endothelial Corneal Dystrophy (FECD) [Phase 2]

See pricing